Suppr超能文献

转移性乳腺癌女性患者生存的预后因素以及疾病原发或继发性质对生存的影响:一项基于法国人群的研究

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.

作者信息

Marshall Esaie M, Bertaut Aurélie, Desmoulins Isabelle, Darut-Jouve Ariane, Ponnelle Tibor, Poillot Marie-Laure, Beltjens Francoise, Arveux Patrick

机构信息

Côte d'Or Breast Cancer Registry, CGFL, Dijon, France.

Research Unit 4184, Faculty of Medicine, University of Burgundy, Dijon, France.

出版信息

Breast J. 2017 Mar;23(2):138-145. doi: 10.1111/tbj.12717. Epub 2016 Dec 9.

Abstract

We aim to determine whether differences in survival exist between two populations of women with metastatic breast cancer (MBC) and to identify prognostic factors of survival after metastasis diagnosis. Data on women with MBC diagnosed between 2000 and 2011 were provided by the Côte d'Or Breast cancer registry. Survival rates and median overall survival (OS) after metastasis diagnosis were determined using the Kaplan-Meier method and prognostic factors were determined in a Cox proportional hazard model. Overall, 282 women with primary MBC and 340 with secondary MBC were included. A 2-year survival rate was significantly better in women with primary MBC (50.8% [95% CI: 47.8-53.8%] versus 44.5% [95% CI: 41.8-47.2%]). However, median OS did not differ between the two groups (p = 0.1). The prognostic factors associated with worst survival were a triple-negative tumor type (p < 10 ), multiple metastases sites (p < 10 ), an older age at metastasis (p < 10 ), and a SBR grade G3 (p = 0.007). OS between women with primary MBC and women with secondary MBC does not seem to differ significantly. This population-based study provides original epidemiological data on French women without any selection bias inherent to hospital cohorts.

摘要

我们旨在确定两组转移性乳腺癌(MBC)女性患者在生存率上是否存在差异,并找出转移诊断后生存的预后因素。2000年至2011年间确诊的MBC女性患者数据由科多尔乳腺癌登记处提供。采用Kaplan-Meier方法确定转移诊断后的生存率和中位总生存期(OS),并在Cox比例风险模型中确定预后因素。总体而言,纳入了282例原发性MBC女性患者和340例继发性MBC女性患者。原发性MBC女性患者的2年生存率显著更高(50.8% [95% CI:47.8 - 53.8%] 对比44.5% [95% CI:41.8 - 47.2%])。然而,两组之间的中位OS没有差异(p = 0.1)。与最差生存相关的预后因素为三阴性肿瘤类型(p < 0.01)、多个转移部位(p < 0.01)、转移时年龄较大(p < 0.01)以及SBR G3级(p = 0.007)。原发性MBC女性患者和继发性MBC女性患者之间的OS似乎没有显著差异。这项基于人群的研究提供了关于法国女性的原始流行病学数据,没有医院队列固有的任何选择偏倚。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验